Novel Biomarkers in Heart Failure with Preserved Ejection Fraction

Heart Failure Clinics

Volumn 10, Issue 3, 2014, Pages 471-479

  Shah, Kevin S ^a   Maisel, Alan S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Biomarkers; Diagnosis; Heart failure; Preserved ejection fraction; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CYSTATIN C; GALECTIN 3; INTERLEUKIN 1 RECEPTOR; NATRIURETIC FACTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ST 2 PROTEIN; TROPONIN; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; TROPONIN T;

HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; REVIEW; AGED; BLOOD; DISEASE COURSE; FEMALE; HEART FAILURE; HEART STROKE VOLUME; MALE; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYNDROME;

AGED; BIOLOGICAL MARKERS; CYSTATIN C; DISEASE PROGRESSION; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; PROGNOSIS; RECEPTORS, CELL SURFACE; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; SYNDROME; TROPONIN T;

EID: 84903393354     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2014.04.005     Document Type: Review

References (84)

1. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
2. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart 2007, 93:1137-1146.
3. Vasan R.S., Benjamin E.J., Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. JAm Coll Cardiol 1995, 26:1565-1574.
4. Owan T.E., Redfield M.M. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005, 47:320-332.
5. Chan M.M., Lam C.S. How do patients with heart failure with preserved ejection fraction die?. Eur J Heart Fail 2013, 15(6):604-613.
6. Heart Failure Society of America, Lindenfeld J., Albert N.M., et al. HFSA 2010 comprehensive heart failure practice guideline. JCard Fail 2010, 16(6):e1-e194.
7. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
8. Lee D.S., Gona P., Vasan R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and blood Institute. Circulation 2009, 119:3070-3077.
9. Bursi F., Weston S.A., Redfield M.M., et al. Systolic and diastolic heart failure in the community. JAMA 2006, 296:2209-2216.
10. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. NEngl J Med 2006, 355:260-269.
11. Fonarow G.C., Stough W.G., Abraham W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. JAm Coll Cardiol 2007, 50:768-777.
12. Yancy C.W., Lopatin M., Stevenson L.W., et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. JAm Coll Cardiol 2006, 47:76-84.
13. Lenzen M.J., Scholte Reimer W.J., Boersma E., et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004, 25:1214-1220.
14. Sanderson J.E. Heart failure with a normal ejection fraction. Heart 2007, 93:155-158.
15. McMurray J., Pfeffer M.A. New therapeutic options in congestive heart failure: part II. Circulation 2002, 105:2223-2228.
16. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
17. Tschoepe C., Westermann D. Heart failure with normal ejection fraction. Pathophysiology, diagnosis, and treatment. Herz 2009, 34:89-96.
18. Lam C.S., Lyass A., Kraigher-Krainer E., et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007, 115:1982-1990.
19. Zile R.M., Baicu C.F., Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. NEngl J Med 2004, 350:1953-1959.
20. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011, 32:670-679.
21. Weber K.T., Brilla C.G., Janicki J.S. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993, 27:341-348.
22. van Heerebeek L., Borbely A., Niessen H.W., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113:1966-1973.
23. Sohn D.W., Kim H.K., Park J.S., et al. Hemodynamic effects of tachycardia in patients with relaxation abnormality: abnormal stroke volume response as an overlooked mechanism of dyspnea associated with tachycardia in diastolic heart failure. JAm Soc Echocardiogr 2007, 20:171-176.
24. Ather S., Chan W., Bozkurt B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. JAm Coll Cardiol 2012, 59:998-1005.
25. Maurer M.S., Hummel S.L. Heart failure with a preserved ejection fraction: what is in a name?. JAm Coll Cardiol 2011, 58:275-277.
26. Mohammed S.F., Borlaug B.A., Roger V.L., et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community based study. Circ Heart Fail 2012, 5:710-719.
27. van Heerebeek L., Franssen C.P., Hamdani N., et al. Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep 2008, 4:13-21.
28. Borbely A., van Heerebeek L., Paulus W.J. Transcriptional and posttranslational modifications of titin: implications for diastole. Circ Res 2009, 104:12-14.
29. Paulus W.J., Tschöpe C. Anovel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. JAm Coll Cardiol 2013, 62(4):263-271.
30. Cleland J.G., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
31. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
32. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. NEngl J Med 2008, 359:2456-2467.
33. Flather M.D., Shibata M.C., Coats A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215-225.
34. Fukuta H., Sane D.C., Brucks S., et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure. Circulation 2005, 112:357-363.
35. Florea V.G., Anand I.S. Biomarkers. Heart Fail Clin 2012, 8(2):207-224.
36. Maisel A.S., Krishnaswamy P., Nowak R.M., Breathing Not Properly Multinational Study Investigators, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. NEngl J Med 2002, 347(3):161-167.
37. Maisel A.S., Daniels L.B. Breathing not properly 10years later: what we have learned and what we still need to learn. JAm Coll Cardiol 2012, 60(4):277-282.
38. Daniels L.B., Maisel A.S. Natriuretic peptides. JAm Coll Cardiol 2007, 50:2357-2368.
39. Januzzi J.L., Rehman S.U., Mohammed A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular dysfunction. JAm Coll Cardiol 2011, 58:1881-1889.
40. Parekh N., Maisel A.S. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Curr Opin Cardiol 2009, 24:155-160.
41. van Veldhuisen D.J., Linssen G.C., Jaarsma T., et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. JAm Coll Cardiol 2013, 61(14):1498-1506.
42. Peacock W.F., De Marco T., Fonarow G.C., ADHERE Investigators, et al. Cardiac troponin and outcome in acute heart failure. NEngl J Med 2008, 358(20):2117-2126.
43. Kociol R.D., Pang P.S., Gheorghiade M., et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. JAm Coll Cardiol 2010, 56:1071-1078.
44. Latini R., Masson S., Anand I.S., et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116:1242-1249.
45. Sato Y., Yamada T., Taniguchi R., et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001, 103:369-374.
46. Dinh W., Nickl W., Futh R., et al. High sensitive troponin T and heart fatty acid binding protein: novel biomarker in heart failure with normal ejection fraction? A cross-sectional study. BMC Cardiovasc Disord 2011, 11:41.
47. Santhanakrishnan R., Chong J.P., Ng T.P., et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012, 14(12):1338-1347.
48. Dumic J., Dabelic S., Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006, 1760:616-635.
49. Yang R.Y., Rabinovich G.A., Liu F.T. Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med 2008, 13:e17-e39.
50. Sharma U.C., Pokharel S., van Brakel T.J., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
51. Lin Y.H., Lin L.Y., Wu Y.W., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96-99.
52. Calvier L., Miana M., Reboul P., et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013, 33:67.
53. Yu L., Ruifrok W.P., Meissner M., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
54. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. JAm Coll Cardiol 2006, 48:1217-1224.
55. Lok D.J., Van Der Meer P., de la Porte P.W., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010, 99:323-328.
56. Anand I.S., Rector T.S., Kuskowski M., et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013, 15(5):511-518.
57. van der Velde A.R., Gullestad L., Ueland T., et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013, 6:219-226.
58. Gopal D.M., Kommineni M., Ayalon N., et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. JAm Heart Assoc 2012, 1:e000760.
59. Azibani F., Benard L., Schlossarek S., et al. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension 2012, 59:1179-1187.
60. Brilla C.G. Aldosterone and myocardial fibrosis in heart failure. Herz 2000, 25(3):299-306.
61. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
62. de Boer R.A., Edelmann F., Cohen-Solal A., et al. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013, 15(10):1095-1101.
63. Sanada S., Hakuno D., Higgins L.J., et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. JClin Invest 2007, 117:1538-1549.
64. Weinberg E.O., Shimpo M., De Keulenaer G.W., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 3:2961-2966.
65. Weinberg E.O., Shimpo M., Hurwitz S., et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
66. Weir R.A., Miller A.M., Murphy G.E., et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. JAm Coll Cardiol 2010, 55:243-250.
67. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. JAm Coll Cardiol 2007, 50:607-613.
68. Mueller T., Dieplinger B., Gegenhuber A., et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008, 54:752-756.
69. Bayes-Genis A., de Antonio M., Vila J., et al. Head-to head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. JAm Coll Cardiol 2014, 63(2):158-166.
70. Shah R.V., Chen-Tournoux A.A., Picard M.H., et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009, 2:311-331.
71. Manzano-Fernández S., Mueller T., Pascual-Figal D., et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011, 107(2):259-267.
72. Seki K., Sanada S., Kudinova A.Y., et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2:684-691.
73. Mann D.L., Bristow M.R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005, 111:2837-2849.
74. Sugihara N., Genda A., Shimizu M., et al. Diastolic dysfunction and its relation to myocardial fibrosis in essential hypertension. JCardiol 1988, 18:353-361.
75. Borbely A., van der Velden J., Papp Z., et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005, 111:774-781.
76. Kjeldsen L., Johnsen A.H., Sengeløv H., et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. JBiol Chem 1993, 268:10425-10432.
77. Flower D.R. The lipocalin protein family: structure and function. Biochem J 1996, 318:1-14.
78. Goetz D.H., Willie S.T., Armen R.S., et al. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 2000, 39:1935-1941.
79. Kusaka M., Kuroyanagi Y., Mori T., et al. Serum neutrophil gelatinase-associated lipocalin as a predictor of organ recovery from delayed graft function after kidney transplantation from donors after cardiac death. Cell Transplant 2008, 1(2):129-134.
80. Cruz D.N., De Cal M., Garzotto F., et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 2010, 36(3):444-451.
81. Devarajan P. NGAL in acute kidney injury: from serendipity to utility. Am J kidney Dis 2008, 52(3):395.
82. Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002, 40:221-226.
83. Herget-Rosenthal S., Marggraf G., Hüsing J., et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004, 66:1115-1122.
84. Fleming T.R., Powers J.H. Biomarkers and surrogate endpoints in clinical trials. Stat Med 2012, 31(25):2973-2984.